Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, reports on the use of momelotinib, a JAK inhibitor, in intermediate/high-risk myelofibrosis patients, as well as the Phase III MOMENTUM study (NCT04173494), investigating the use of momelotinib versus danazol in symptomatic and anemic myelofibrosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
